Seiji Nukui

USPTO Granted Patents = 23 (Patent Applications = 2)

CIPO Patents = 3

EPO Patents = 7 (Patent Applications = 4)

Average Co-Inventor Count = 6.2

ph-index = 8

Forward Citations = 175(Granted Patents)

Location History:

Tokyo, JP (2004)
Aichi-ken, JP (2002 - 2006)
Chita-gun, JP (2009)
San Diego, CA (US) (2006 - 2023)

Company Filing History:

Nitto-denko Corporation

patents

2 out of 2,538

Warner-lambert Company

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12319643 - Ionizable compounds and compositions and uses thereof (2025-06-03),

2. 11780853 - Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors (2023-10-10),

3. 11384051 - Ionizable compounds and compositions and uses thereof (2022-07-12),

4. 11220518 - Substituted n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as protein kinase C inhibitors (2022-01-11),

5. 10316045 - Substituted pyrrolo[3,4-c]pyrazoles as pkc kinase inhibitors (2019-06-11),

6. 10167253 - Ionizable compounds and compositions and uses thereof (2019-01-01),

7. 9518060 - Substituted pyrrolo[3,4-c]pyrazoles as PKC kinase inhibitors (2016-12-13),

8. 9078926 - Polymer conjugates with a linker (2015-07-14),

9. 8999981 - [object Object] (2015-04-07),

10. 8877761 - N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors (2014-11-04),

11. 8183255 - N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors (2012-05-22),

12. 8119624 - Fused phenyl amido heterocyclic compounds (2012-02-21),

13. 8114871 - 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives (2012-02-14),

14. 7842713 - Fused phenyl amido heterocyclic compounds (2010-11-30),

15. 7479564 - Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents (2009-01-20),

Title: Seiji Nukui: Innovator in Biopharmaceuticals

Introduction

Seiji Nukui, based in San Diego, California, is a notable inventor with an impressive portfolio of 22 patents. His work primarily focuses on advancements in biopharmaceuticals and therapeutics, specifically in the development of innovative compounds and compositions that target various medical applications.

Latest Patents

Among his latest patents, one describes "Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors," which presents new compounds to inhibit protein kinase C beta II. Another recent patent focuses on "Ionizable compounds and compositions and uses thereof," which includes methods for creating nanoparticle compositions intended for use in drug delivery and encapsulation of active agents, such as nucleic acid agents.

Career Highlights

Seiji Nukui has worked for prominent companies, including Pfizer Corporation, where he contributed to several innovative projects in the pharmaceutical industry. His expertise has played a crucial role in developing new therapeutic options for various medical conditions. Additionally, he was employed at Nitto Denko Corporation, further showcasing his diverse experience in research and development.

Collaborations

Throughout his career, Seiji has collaborated with notable colleagues, including Chunfeng Yin and Hui Li. These partnerships have enabled him to leverage diverse perspectives and expertise, enhancing the success of his patents and innovations.

Conclusion

Seiji Nukui stands out as a vital contributor in the field of biopharmaceuticals. His innovative patents and collaborative efforts continue to influence advancements in medical science, showcasing his dedication to improving health outcomes through groundbreaking research and development.

This text is generated by artificial intelligence and may not be accurate.